Targeting the STING Pathway in Breast Cancer
Author:
Publisher
Springer International Publishing
Link
https://link.springer.com/content/pdf/10.1007/13905_2024_41
Reference65 articles.
1. Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im S-A, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA (2018) Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 379(22):2108–2121. https://doi.org/10.1056/nejmoa1809615
2. Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im S-A, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Guo Z, Zhao J, Aktan G, Karantza V, Schmid P, Luis F, Gonzalo GA, Diego K, Ruben K, Matias M, Mirta V, Sally B-H, Stephen B, Philip C, Sherene L, Dhanusha S, Andrea G, Donatienne T, Carlos B, Leandro B, Fabiano C, Ruffo DFJ, Roberto H, Domicio Carvalho L, Fernando Cezar Toniazzi L, Roberto Odebrecht R, Antonio Orlando SN, Felipe S, David C, Danielle C, Cristiano F, Xinni S, Joanne Y, Alejandro A, Carlos G, Claudio S, Cesar S, Eduardo Y, Alvaro GD, Jesus S, Petra H, Zdenek K, Bohuslav M, Katarina P, Jana P, Vesna G, Erik J, Jeanette J, Soren L, Tamas L, Herve B, Isabelle D, Anthony G, Anne-Claire H-B, Luis T, Jens-Uwe B, Peter F, Dirk F, Nadia H, Jens H, Anna KFDS, Christian K, Sibylle L, Diana L, Tjoung-Won P-S, Raquel Von S, Pauline W, Louis C, Ava K, Kai Cheong Roger N, Peter A, Tibor C, Zsuzsanna K, Laszlo L, Karoly M, Gabor R, John C, Catherine K, Seamus OR, Saverio C, Antonietta D, Enrico R, Tomoyuki A, Takaaki F, Kenichi I, Takashi I, Yoshinori I, Tsutomu I, Hiroji I, Yoshimasa K, Koji M, Yasuo M, Hirofumi M, Seigo N, Naoki N, Shoichiro O, Akihiko O, Yasuaki S, Eiji S, Masato T, Yuko T, Kenji T, Koichiro T, Junichiro W, Naohito Y, Yutaka Y, Teruo Y, Anita B, Mastura MY, Angel GV, Alejandro JR, Jorge MR, Flavia M-V, Jessica RC, Karin B, Vivianne T-H, David P, Ewa C, Ewa N-Z, Zbigniew N, Barbara R, Joanna S, Cezary S, Rafal T, Bogdan Z, Alexander A, Natalia F, Oleg L, Andrey M, Vladimir M, Guzel M, Jin Hee A, Seock-Ah I, Keun Seok L, Kwong Hwa P, Yeon Hee P, Begona BDLH, Javier C, Josefina CJ, Luis DLCM, Jose GS, Maria G, Esther H, Esther ZA, Chien-Ting L, Mei-Ching L, Chiun-Sheng H, Chao-Jung T, Ling-Ming T, Cagatay A, Gul B, Irfan C, Erhan G, Seyda G, Nil MM, Mustafa O, Ozgur O, Sinan Y, Steve C, Janine G, Iain M, Peter S, Nicholas T, Mark T, Christopher T, Duncan W, Hryhoriy A, Oleksandr B, Igor B, Oleksii K, Olena K, Hanna K, Anna K, Iurii L, Alla N, Natalya O, Olga P, Andrii R, Sergii S, Yaroslav S, Dmytro T, Grygorii U, Ihor V, Sibel B, Madhu C, Michael C, Patrick C, Scott C, Jennifer D, Keerthi G, Jeffrey H, Kent H, William I, Randa L, Janice L, Raul M, Susan M, Rita N, Ira O, Coral O, Timothy P, Amit P, Brian P, Hope R, Irina R, Michael S, Robert S, Michael S, Laura S, Bradley S, Michaela T, Frances V-A (2020) Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396(10265):1817–1828. https://doi.org/10.1016/s0140-6736(20)32531-9
3. Parkes EE, Walker SM, Taggart LE, Mccabe N, Knight LA, Wilkinson R, Mccloskey KD, Buckley NE, Savage KI, Salto-Tellez M, Mcquaid S, Harte MT, Mullan PB, Harkin DP, Kennedy RD (2017) Activation of STING-dependent innate immune signaling by S-phase-specific DNA damage in breast cancer. J Natl Cancer Inst 109(1):djw199. https://doi.org/10.1093/jnci/djw199
4. An X, Zhu Y, Zheng T, Wang G, Zhang M, Li J, Ji H, Li S, Yang S, Xu D, Li Z, Wang T, He Y, Zhang L, Yang W, Zhao R, Hao D, Li X (2019) An analysis of the expression and association with immune cell infiltration of the cGAS/STING pathway in pan-cancer. Mol Ther Nucleic Acids 14:80–89. https://doi.org/10.1016/j.omtn.2018.11.003
5. Flood BA, Higgs EF, Li S, Luke JJ, Gajewski TF (2019) STING pathway agonism as a cancer therapeutic. Immunol Rev 290(1):24–38. https://doi.org/10.1111/imr.12765
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3